EHAB
Enhabit Inc
$
7.570
- Overview
- Forecast
- Valuation
- Earnings
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
7.775
Open
7.600
VWAP
7.63
Vol
491.80K
Mkt Cap
383.73M
Low
7.541
Amount
3.75M
EV/EBITDA(TTM)
12.13
Total Shares
50.16M
EV
854.91M
EV/OCF(TTM)
16.19
P/S(TTM)
0.37
Enhabit, Inc. is a provider of home health and hospice services in the United States. Its segments include Home Health and Hospice. The Home Health segment provides a comprehensive range of Medicare-certified skilled home health services, including skilled nursing, physical, occupational and speech therapy, medical social work, and home health aide services. It works closely with patients, families, caregivers, and physicians to deliver data-driven, evidence-based care plans focused on patient needs and goals. Its home health services are provided by nurses, physical, occupational and speech therapists, medical social workers, and home health aides. The Hospice segment provides hospice services to terminally ill patients and their families. Hospice care focuses on the quality of life for patients experiencing an advanced, life- limiting illness by treating the symptoms of the disease, rather than the disease itself. It operates about 115 hospice agencies and 255 home health agencies.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q3
FY2025Q4
FY2026Q1
267.07M
+5.31%
0.119
+297.97%
271.87M
+5.29%
0.142
+254.05%
270.69M
+4.15%
0.116
+16.4%
Estimates Revision
The market is revising No Change the revenue expectations for Enhabit, Inc. (EHAB) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -27.70%.
Revenue Estimates for FY2025
No Change
0.00%
In Past 3 Month
EPS Estimates for FY2025
No Change
0.00%
In Past 3 Month
Stock Price
Go Down
-27.70%
In Past 3 Month
2 Analyst Rating
25.50% Upside
Wall Street analysts forecast EHAB stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for EHAB is 9.50 USD with a low forecast of 9.00 USD and a high forecast of 10.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
0 Buy
2 Hold
0 Sell
Hold
25.50% Upside
Current: 7.570
Low
9.00
Averages
9.50
High
10.00
25.50% Upside
Current: 7.570
Low
9.00
Averages
9.50
High
10.00
UBS
Neutral
downgrade
$10
2025-08-08
New
Reason
UBS
Price Target
$10
2025-08-08
New
downgrade
Neutral
Reason
UBS lowered the firm's price target on Enhabit to $8.50 from $10 and keeps a Neutral rating on the shares. Enhabit's Q2 results were largely positive, but the company is focused on combating the home health rate cut, the analyst tells investors in a research note.
Jefferies
Brian Tanquilut
Hold
to
Strong Buy
Upgrades
$8.25 → $9.5
2024-12-09
Reason
Jefferies
Brian Tanquilut
Price Target
$8.25 → $9.5
2024-12-09
Upgrades
Hold
to
Strong Buy
Reason
Jefferies upgraded Enhabit (EHAB) to Buy from Hold with a price target of $9.50, up from $8.25. The company's announcement of a new contract with UnitedHealth (UNH) that pays it a higher rate than its previous agreement eliminates an overhang and execution risk associated with potential revenue and EBITDA losses, the analyst tells investors in a research note. The firm believes the contract should enable Enhabit to focus more on driving growth rather than plugging the potential earnings hole that would have been caused by a UnitedHealth exit.
Leerink Partners
Whit Mayo
Hold
Reiterates
$8.5 → $8
2024-11-19
Reason
Leerink Partners
Whit Mayo
Price Target
$8.5 → $8
2024-11-19
Reiterates
Hold
Reason
See All Ratings
Valuation Metrics
The current forward P/E ratio for Enhabit Inc (EHAB.N) is 15.50, compared to its 5-year average forward P/E of 32.24. For a more detailed relative valuation and DCF analysis to assess Enhabit Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
Undervalued
5Y Average PE
32.24
Current PE
15.50
Overvalued PE
48.88
Undervalued PE
15.60
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
Undervalued
5Y Average EV/EBITDA
10.50
Current EV/EBITDA
8.54
Overvalued EV/EBITDA
11.99
Undervalued EV/EBITDA
9.01
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
Undervalued
5Y Average PS
0.51
Current PS
0.34
Overvalued PS
0.65
Undervalued PS
0.37
Financials
Annual
Quarterly
FY2025Q2
YoY :
+2.11%
266.10M
Total Revenue
FY2025Q2
YoY :
+13.12%
18.10M
Operating Profit
FY2025Q2
YoY :
+1325.00%
5.70M
Net Income after Tax
FY2025Q2
0.10
EPS - Diluted
FY2025Q2
YoY :
-2.25%
8.70M
Free Cash Flow
FY2025Q2
YoY :
+0.92%
46.94
Gross Profit Margin - %
FY2025Q2
YoY :
+55.74%
4.75
FCF Margin - %
FY2025Q2
YoY :
+1326.67%
2.14
Net Margin - %
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
9.4K
USD
1
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
1
76.4K
USD
Months
3-6
0
0.0
USD
Months
6-9
2
166.9K
USD
Months
0-12
2
77.2K
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
9.9K
Volume
1
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
3
838.8K
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
9.4K
USD
1
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
1
76.4K
USD
Months
3-6
0
0.0
USD
Months
6-9
2
166.9K
USD
Months
0-12
2
77.2K
USD
Months
EHAB News & Events
Events Timeline
2025-07-01 (ET)
2025-07-01
12:01:16
Enhabit falls -16.3%
2025-07-01
10:00:02
Enhabit falls -14.4%
2025-07-01
09:52:23
Home health stocks under pressure following proposed rate cuts
Sign Up For More Events
Sign Up For More Events
News
9.5
08-07NASDAQ.COMEnhabit (EHAB) Q2 EPS Jumps 86%
5.0
08-06NewsfilterEnhabit Home Health & Hospice Announces CEO Transition Plan
3.0
07-17NewsfilterEnhabit Home Health & Hospice Announces Date of 2025 Second Quarter Earnings Call
Sign Up For More News
People Also Watch
FAQ
What is Enhabit Inc (EHAB) stock price today?
The current price of EHAB is 7.57 USD — it has increased 0.4 % in the last trading day.
What is Enhabit Inc (EHAB)'s business?
What is the price predicton of EHAB Stock?
What is Enhabit Inc (EHAB)'s revenue for the last quarter?
What is Enhabit Inc (EHAB)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Enhabit Inc (EHAB)'s fundamentals?
How many employees does Enhabit Inc (EHAB). have?